

AMENDMENTS TO THE CLAIMS

1. (cancelled)
2. (cancelled)
3. (currently amended) An isolated antibody that selectively binds to a polypeptide, ~~of claim 2~~ wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.
- 4-23. (canceled)
24. (new) An isolated antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2.
25. (new) The antibody of claim 3, wherein the antibody is a monoclonal antibody.
26. (new) The antibody of claim 24, wherein the antibody is a monoclonal antibody.
27. (new) The antibody of claim 3, wherein the antibody is coupled to a detectable substance.
28. (new) The antibody of claim 24, wherein the antibody is coupled to a detectable substance.
29. (new) The antibody of claim 25, wherein the antibody is coupled to a detectable substance.

30. (new) The antibody of claim 26, wherein the antibody is coupled to a detectable substance.
31. (new) A composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.
32. (new) A composition comprising the antibody of claim 24 and a pharmaceutically acceptable carrier.
33. (new) A composition comprising the antibody of claim 25 and a pharmaceutically acceptable carrier.
34. (new) A composition comprising the antibody of claim 26 and a pharmaceutically acceptable carrier.
35. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
- a) an Fab fragment;
 - b) an F(ab')₂ fragment; and
 - c) an Fv fragment.
36. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
- a) an Fab fragment;
 - b) an F(ab')₂ fragment; and
 - c) an Fv fragment.